Francisco Vera-Badillo

6PUBLICATIONS
68CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersChemotherapyEpidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Nov 08, 2024
Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer.

Eric Winquist, Sebastien J Hotte, Kim Chi

|Apr 24, 2024
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer.

Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz

|Jun 20, 2022
Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?

Adi Kartolo, Ian F Tannock, Francisco E Vera Badillo

|Feb 21, 2022
Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care?

Simon Van Wambeke, Francisco Emilio Vera-Badillo, Bishal Gyawali

|Dec 22, 2021
Treatment Adherence Issues for Adolescents and Young Adults with Testicular Cancer Due to Changes in the Public Health System in Mexico.

Saul Campos-Gomez, Ana M Vera-Rodriguez, Samuel Rivera-Rivera

|Dec 20, 2021
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.

Martin R Stockler, Andrew J Martin, Ian D Davis

Pageof 1